Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 7/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 5/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437152 | 0.86 | NPC1 (0.44) | HIF1ANPC1RAB9ASMN1; SMN2OPRM1 | |
| SCHEMBL24437265 | 0.86 | RAB9A (0.39) | HIF1ANPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL24437167 | 0.80 | NPC1 (0.42) | HIF1ANPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL24437207 | 0.78 | CRACR2A (0.45) | NPC1RAB9ASMN1; SMN2KDM4CTSHR | |
| SCHEMBL24437151 | 0.74 | CNR1 (0.48) | ROCK2KDM4C | |
| SCHEMBL24437201 | 0.74 | STIM1 (0.47) | NPC1RAB9AKMT2ASMN1; SMN2TSHR | |
| SCHEMBL24437195 | 0.73 | CNR1 (0.42) | ROCK2SMN1; SMN2KDM4C | |
| SCHEMBL24437154 | 0.73 | DYRK1A (0.49) | ROCK2SMN1; SMN2KDM4C | |
| SCHEMBL24437272 | 0.73 | ROCK2 (0.41) | RAB9AROCK2PIM1PIM3PIM2 | |
| SCHEMBL24437333 | 0.73 | WNT1 (0.39) | NPC1RAB9AROCK2SMN1; SMN2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | HIF1A 1367/4885NPC1 408/4885RAB9A 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.